HK Stock Market Move | CARSGEN-B(02171) rose by more than 7%, the Class B medical insurance catalog will be released during the year, institutions say CAR-T is expected to enter the catalog.

CARSGEN-B (02171) rose more than 7%, as of the time of writing, it has risen by 6.63%, trading at 10.94 Hong Kong dollars, with a turnover of 36.2309 million Hong Kong dollars. On the news front, a relevant person from the National Medical Insurance Bureau stated that the first version of the medical insurance category C list will be released by 2025. Zhongtai International pointed out that drugs that have passed formal review and expert evaluation in the C category list may be given priority, such as CAR-T, ADC, etc., drugs that were not ultimately included in the basic medical insurance list, providing a potential opening for payment in the field of domestic innovative drugs. It is reported that four CAR-T cell therapies, including Zeversolexin injection from Koji Pharmaceutical, did not appear in the 2024 national medical insurance list. In addition, Koji Pharmaceutical recently announced that its independently developed universal CAR-T cell therapy candidate product targeting CD19/CD20, KJ-C2219, has completed dosing of the first subject in an investigator-initiated clinical trial (IIT). It is reported that KJ-C2219 is developed based on the THANK-uPlus platform and is planned to be used in the treatment of blood malignancies and autoimmune diseases, currently conducting an investigator-initiated clinical trial in China for relapsed/refractory B-cell non-Hodgkin's lymphoma (R/RB-NHL).